FDA aims to pull Shire's blood pressure drug from the market

08/16/2010 | Wall Street Journal, The

The FDA is seeking to withdraw Shire's ProAmatine from the market because the drugmaker failed to conduct follow-up trials to demonstrate the drug's clinical benefit in patients with orthostatic hypotension. The treatment, generically known as midodrine hydrochloride, received accelerated approval in 1996.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN